Fig. 7
From: Current trends and challenges in cancer management and therapy using designer nanomaterials
(reproduced with permission from [235])
Scheme representing the formulation of doxorubicin loaded PEGylated liposome, and doxorubicin loaded lactoferrin modified PEGylated liposome (a); effect of cell viability of free DOX and the liposomal formulations evaluated by MTT assay in HepG2, BEL7402, and SMMC7721 cells at different time intervals (b); relative tumor volume of various liposomal formulations injected to tumor-bearing mice through tail veins every 7Â days at a dose of 5Â mg/kg DOX (c); change in the body weight of tumor-bearing mice after each treatment (d); image of tumors excised on 21st day from each treatment group (e); relative tumor volume at the time of sacrifice from each treatment group (f); tumor weight at the time of sacrifice from each treatment group (g)